Holiday Sale | Save 50%
SubscribeLogin
Holiday Sale | Save 50%
Published

First phase of BiVACOR early feasibility study completed - Cardiovascular News

Summary by Cardiovascular News
BiVACOR has announced the successful completion of the first phase of the US Food and Drug Administration (FDA) early feasibility study, with five patients receiving the BiVACOR total artificial heart (TAH) between July and November 2024. The study evaluates the safety and performance of the BiVACOR TAH system in patients as a bridge to donor heart transplant. This study assessed the feasibility of using the BiVACOR TAH system to support adult p…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDAFDA
Houston, TexasHouston, Texas
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal